Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in FUM?
Futura Medical plc.: THE INVESTMENT CASE

Futura shares double after successful clinical trial

It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.
Futura shares double after successful clinical trial
INVESTMENT OVERVIEW: FUM The Big Picture
Futura's gel acts more quickly than traditional remedies such as Viagra.

Shares in Futura Medical PLC (LON:FUM) doubled in value after the company announced a pivotal clinical trial of its gel for erectile dysfunction (ED) had been a resounding success.

It means Futura now has a differentiated product in a market worth US$5bn currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.

City broker N+1 Singer said it thought the firm’s treatment, MED2002, had “significant potential” following the publication of a study that “successfully demonstrated” efficacy, safety and speed of onset.

MED2002 scored success across all groups tested – mild, moderate and severe cases – but did particularly well in men with mild ED.

Some 82% with the mild form of the condition said the gel began working within 10 minutes, with 54% reporting onset within five minutes.

No safety concerns were registered, which means the gel could be positioned as a consumer health product at the right dosage as well as being a prescription-based medicine. 

Futura said the results will form the basis of “commercialisation strategy” for MED2002.

“The headline data from the study indicate that we have a breakthrough ED product that is not only effective but may also combine potentially the world's fastest speed of onset for an ED treatment with a very favourable safety profile,” said chief executive James Barder.

“We will carry out further analysis of the results in the next few days and are very excited by the commercial potential of this product."

By 11.30am, the shares were up 31p, or 108%, to 59.5p, valuing the business at £43mln.

“We believe the market potential is significant, and will update our forecasts as soon as the commercialisation strategy for the product has been clarified,” said the City broker N+1 Singer in a note.

Research commissioned by Futura found a widespread dissatisfaction with the current crop of ED pills, with the speed of onset being the most common complaint.

MED2002 provides a far more rapid solution to what's out there currently. It takes five to ten minutes before the effect is felt versus 20 for the likes of Viagra.

All of this provides an opportunity: a ready-made market of men who either can’t or don’t like taking the current help available.

It is probably more appropriate to classify Futura as a med-tech rather than a traditional pharma or biotech firm. And this is a crucial distinction.

For what it has created is a mode of action that gets drugs through the skin more quickly and effectively than other gels of this type.

It is a patented delivery method. For erectile dysfunction, it is incorporated with glyceryl trinitrate, which has been used to treat angina for decades.

You won’t be surprised to learn, then, the technology is being developed to carry traditional and well tolerated painkillers quickly and effectively to the point they are most needed.

It means the company is not a one trick pony – it has a pipeline quick-to-market products that have consumer and medical indications.

Ian_55ae0ddd437b7.jpg


Register here to be notified of future FUM Company articles
View full FUM profile View Profile

Futura Medical plc. Timeline

Article
January 10 2017

Related Articles

cancer cells
January 24 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year
antibiotic.jpg
April 18 2017
Iclaprim is one of the next-generation of antibiotics and it will be used, initially at least, to treat acute bacterial skin and skin structure infections
picture of Paris
April 04 2017
Data from the European head and neck trial with lead product NBTXR3 will be presented at the ASCO meeting in June

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use